Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 3/20 | 0.30 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10268367 | 0.89 | MPO (0.41) | MPOC5AR1LRRK2PSMB8PSMB9 | |
| SCHEMBL22084225 | 0.83 | MPO (0.45) | MPOC5AR1PSMB8PSMB9PSMB5 | |
| Hydrochloric Acid SCHEMBL22031938 | 0.83 | MPO (0.45) | MPOC5AR1PSMB8PSMB9PSMB5 | |
| SCHEMBL16666980 | 0.83 | MPO (0.42) | MPOC5AR1PSMB8PSMB9PSMB5 | |
| SCHEMBL251511 | 0.83 | MPO (0.42) | MPOC5AR1PSMB8PSMB9PSMB5 | |
| SCHEMBL10202942 | 0.80 | MPO (0.41) | MPOLRRK2PSMB8PSMB9PSMB5 | |
| SCHEMBL22549676 | 0.78 | MPO (0.39) | MPOPSMB8PSMB9PSMB5NTRK1 | |
| SCHEMBL19851045 | 0.77 | KDM4E (0.36) | MPONPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15677575 | 0.75 | MPO (0.36) | MPOLRRK2 | |
| SCHEMBL24258800 | 0.75 | MPO (0.38) | MPOPSMB8PSMB9PSMB5CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | ASTECH. CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | ASTECH. CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| EP-2865669-A1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2015-04-29 | — | — | EP | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| EP-2588197-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012003392-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | MPO 4110/4885C5AR1 2665/4885LRRK2 862/4885 |
| US-20150141409-A1 | NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF | REV1, GRPR, SI | MPO 126/4885C5AR1 2019/4885LRRK2 3802/4885 |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | MPO 2327/4885C5AR1 259/4885LRRK2 3009/4885 |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | MPO 4110/4885C5AR1 2665/4885LRRK2 862/4885 |
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | MC2R, NR3C2, AVPR1B | MPO 3806/4885C5AR1 713/4885LRRK2 1070/4885 |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | MPO 3914/4885C5AR1 3427/4885LRRK2 1160/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | MPO 3085/4885C5AR1 28/4885LRRK2 3603/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | MPO 4809/4885C5AR1 4087/4885LRRK2 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.